<DOC>
	<DOCNO>NCT02390882</DOCNO>
	<brief_summary>The main objective study evaluate efficacy safety ( Tamsulosin ) HGP0412 HIP1402 patient Benign Prostatic Hyperplasia</brief_summary>
	<brief_title>A Phase 3 Clinical Trial Evaluate Efficacy Safety HGP0412 HIP1402 Patients With BPH</brief_title>
	<detailed_description>A multicenter , randomize , double-blind , phase 3 clinical trial evaluate efficacy safety ( Tamsulosin ) HGP0412 HIP1402 patient benign prostatic hyperplasia</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>age &gt; =45 , male , diagnose BPH , Total IPSS &gt; =13 Hypersensitivity investigational product component PSA &gt; =4ng/ml</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>